Literature DB >> 22124621

A prospective survey of febrile events in hematological malignancies.

L Pagano1, M Caira2, G Rossi16, M Tumbarello4, R Fanci5, M G Garzia6, N Vianelli7, N Filardi8, P De Fabritiis9, A Beltrame10, M Musso11, A Piccin12, A Cuneo13, C Cattaneo3, T Aloisi14, M Riva15, G Rossi16, U Salvadori17, M Brugiatelli18, S Sannicolò19, M Morselli20, A Bonini21, P Viale22, A Nosari15, F Aversa14.   

Abstract

The Hema e-Chart prospectively collected data on febrile events (FEs) in hematological malignancy patients (HMs). The aim of the study was to assess the number, causes and outcome of HM-related FEs. Data were collected in a computerized registry that systematically approached the study and the evolution of FEs developing in a cohort of adult HMs who were admitted to 19 hematology departments in Italy from March 2007 to December 2008. A total of 869 FEs in 3,197 patients with newly diagnosed HMs were recorded. Fever of unidentified origin (FUO) was observed in 386 cases (44.4%). The other causes of FE were identified as noninfectious in 48 cases (5.5%) and infectious in 435 cases (50.1%). Bacteria were the most common cause of infectious FEs (301 cases), followed by fungi (95 cases), and viruses (7 cases). Mixed agents were isolated in 32 episodes. The attributable mortality rate was 6.7% (58 FEs). No deaths were observed in viral infection or in the noninfectious groups, while 25 deaths were due to FUO, 16 to bacterial infections, 14 to fungal infections, and three to mixed infections. The Hema e-Chart provided a complete system for the epidemiological study of infectious complications in HMs.

Entities:  

Mesh:

Year:  2011        PMID: 22124621     DOI: 10.1007/s00277-011-1373-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  18 in total

Review 1.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

2.  An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.

Authors:  Ritvan Kara Ali; Serkan Surme; Ilker Inanc Balkan; Ayse Salihoglu; Meryem Sahin Ozdemir; Yusuf Ozdemir; Bilgul Mete; Gunay Can; Muhlis Cem Ar; Fehmi Tabak; Nese Saltoglu
Journal:  Ann Hematol       Date:  2020-06-20       Impact factor: 3.673

3.  Prior infections are associated with increased mortality from subsequent blood-stream infections among patients with hematological malignancies.

Authors:  J A Greenberg; M Z David; D L Pitrak; J B Hall; J P Kress
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-03       Impact factor: 3.267

4.  Neoplastic fever in patients with bone and soft tissue sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Takao Matsubara; Kunihiro Asanuma; Akihiro Sudo
Journal:  Mol Clin Oncol       Date:  2016-09-21

5.  Feasibility of trimethoprim/sulfamethoxazole desensitization therapy in hematological diseases.

Authors:  Shuto Negishi; Kotaro Miyao; Fumiya Ohara; Kenta Motegi; Hiroya Wakabayashi; Hirofumi Yokota; Shihomi Kuwano; Yuki Takeuchi; Hitomi Sawa; Yuichiro Inagaki; Masashi Sawa
Journal:  Clin Exp Med       Date:  2022-08-17       Impact factor: 5.057

6.  Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective study.

Authors:  Xiaoming Fei; Fang Lei; Haifeng Zhang; Hua Lu; Yan Zhu; Yu Tang
Journal:  Support Care Cancer       Date:  2016-01-23       Impact factor: 3.603

7.  Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Morena Caira; Anna Candoni; Domenico Pastore; Chiara Cattaneo; Rosa Fanci; Annamaria Nosari; Antonio Spadea; Alessandro Busca; Nicola Vianelli; Teresa Spanu; Livio Pagano
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

8.  IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.

Authors:  Gerardo Musuraca; Serena De Matteis; Roberta Napolitano; Cristina Papayannidis; Viviana Guadagnuolo; Francesco Fabbri; Delia Cangini; Michela Ceccolini; Maria Benedetta Giannini; Alessandro Lucchesi; Sonia Ronconi; Paolo Mariotti; Paolo Savini; Monica Tani; Pier Paolo Fattori; Massimo Guidoboni; Giovanni Martinelli; Wainer Zoli; Dino Amadori; Silvia Carloni
Journal:  J Transl Med       Date:  2015-07-15       Impact factor: 5.531

Review 9.  Tuberculosis in patients with haematological malignancies.

Authors:  Luis Anibarro; Alberto Pena
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

10.  Infectious complications in chronic lymphocytic leukemia.

Authors:  Annamaria Nosari
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-05       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.